Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy

被引:33
作者
Chan, Gabriel [1 ]
Hassanain, Mazen [4 ]
Chaudhury, Prosanto [4 ]
Vrochides, Dionisios [4 ]
Neville, Amy [4 ]
Cesari, Matthew [3 ]
Kavan, Petr [2 ,5 ]
Marcus, Victoria [3 ]
Metrakos, Peter [4 ]
机构
[1] Maisonneuve Rosemont Hosp, Dept Surg, Montreal, PQ, Canada
[2] McGill Univ, Dept Oncol, Ctr Hlth, Montreal, PQ, Canada
[3] McGill Univ, Dept Pathol, Ctr Hlth, Montreal, PQ, Canada
[4] McGill Univ, Div Hepatobiliary & Transplant Surg, Ctr Hlth, Montreal, PQ, Canada
[5] McGill Univ, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada
关键词
hepatectomy; neoadjuvant chemotherapy; neoplasm metastasis; survival; recurrence; LONG-TERM SURVIVAL; HEPATIC RESECTION; TUMOR-REGRESSION; CANCER; SURGERY; 5-FLUOROURACIL; HEPATECTOMY; LEUCOVORIN; RECURRENCE; IRINOTECAN;
D O I
10.1111/j.1477-2574.2010.00170.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The complete resection of liver metastases from colorectal cancer is the major determinant of longterm survival. The effectiveness of current chemotherapy regimens has made treatment algorithms more flexible and resulted in many different options. Recently, the pathological response to chemotherapy has emerged as another important prognostic marker. Different systems have been used to grade the pathological response in these patients. Methods: This study prospectively evaluates the prognostic value of the pathological response grade (PRG) in liver metastases treated with neoadjuvant chemotherapy. Results: Between 2002 and 2006, 50 patients were treated with a sandwich chemotherapy regimen and underwent liver resection. Complete resection was achieved in 45 patients (90%). A strong pathological response to chemotherapy (<10% viable tumour cells in all lesions) was seen in 17 patients (34%). It was associated with a statistically significant longer overall survival (P = 0.019) and was also identified on multivariate analysis as an independent predictor of survival (odds ratio = 243). Conclusions: This pilot study demonstrates the prognostic potential of the PRG, which could be used clinically to select patients for an aggressive multimodal adjuvant algorithm. Larger multicentre studies are required to validate this particular grading system. The keys to longterm survival are resectability and chemo-responsiveness.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 50 条
  • [21] Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis
    Wakai, Toshifumi
    Shirai, Yoshio
    Sakata, Jun
    Kameyama, Hitoshi
    Nogami, Hitoshi
    Iiai, Tsuneo
    Ajioka, Yoichi
    Hatakeyama, Katsuyoshi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (04): : 308 - 314
  • [22] Effect of Neoadjuvant Chemotherapy in Patients with Colorectal Cancer Liver Metastases
    Sui, Kenta
    Okabayashi, Takehiro
    Iwata, Jun
    Morita, Sojiro
    Matsumoto, Takatsugu
    Inada, Ryo
    Iiyama, Tatsuo
    Shimada, Yasuhiro
    Kobayashi, Michiya
    SURGICAL TECHNOLOGY INTERNATIONAL-INTERNATIONAL DEVELOPMENTS IN SURGERY AND SURGICAL RESEARCH, 2019, 34
  • [23] Nomogram Incorporating Preoperative Testing Markers for the prediction of Early Recurrence for Colorectal Liver Metastases with Neoadjuvant Chemotherapy followed by Hepatectomy
    Chen, Qichen
    Zhang, Yizhou
    Li, Xingchen
    Huang, Zhen
    Zhao, Hong
    Cai, Jianqiang
    JOURNAL OF CANCER, 2022, 13 (05): : 1758 - 1767
  • [24] Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases
    Lubezky, Nir
    Winograd, Evan
    Papoulas, Michael
    Lahat, Guy
    Shacham-Shmueli, Einat
    Geva, Ravit
    Nakache, Richard
    Klausner, Joseph
    Ben-Haim, Menahem
    JOURNAL OF GASTROINTESTINAL SURGERY, 2013, 17 (03) : 527 - 532
  • [25] Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases
    Miller, Cynthia L.
    Taylor, Martin S.
    Qadan, Motaz
    Deshpande, Vikram
    Worthington, Steven
    Smalley, Robert
    Collura, Chey
    Ryan, David P.
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Murphy, Janet E.
    Parikh, Aparna R.
    Berger, David
    Tanabe, Kenneth K.
    Lillemoe, Keith D.
    Ferrone, Cristina R.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2017, 21 (11) : 1831 - 1840
  • [26] Perioperative chemotherapy for resectable colorectal liver metastases: Where now?
    Jones, R. P.
    Malik, H. Z.
    Fenwick, S. W.
    Poston, G. J.
    EJSO, 2013, 39 (08): : 807 - 811
  • [27] Management of Colorectal Liver Metastases
    Rayar, M.
    Sulpice, L.
    Boudjema, K.
    ONCOLOGIE, 2014, 16 (11-12) : S537 - S542
  • [28] Who Should Receive Neoadjuvant Chemotherapy Prior to Liver Resection for Colorectal Carcinoma Liver Metastases?
    Baldwin, Keith
    Somasundar, Ponnandai
    Espat, N. Joseph
    CURRENT COLORECTAL CANCER REPORTS, 2011, 7 (02) : 168 - 174
  • [29] Implication of primary tumor location for the indication of preoperative chemotherapy in patients with colorectal liver metastases
    Imai, Katsunori
    Yamashita, Yo-ichi
    Miyamoto, Yuji
    Nakao, Yosuke
    Yusa, Toshihiko
    Itoyama, Rumi
    Nakagawa, Shigeki
    Okabe, Hirohisa
    Hiyoshi, Yukiharu
    Nitta, Hidetoshi
    Chikamoto, Akira
    Baba, Hideo
    HPB, 2019, 21 (04) : 405 - 412
  • [30] Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy
    Chloé Serayssol
    Charlotte Maulat
    Florence Breibach
    Fatima-Zohra Mokrane
    Janick Selves
    Rosine Guimbaud
    Philippe Otal
    Bertrand Suc
    Emilie Berard
    Fabrice Muscari
    World Journal of Gastrointestinal Oncology, 2019, 11 (04) : 295 - 309